PAUL MAYOMBOLA: Open Payments
NPI 1902283534 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$356 in 12 payments from 5 companies in 2025. Trend: 2023 $386 · 2024 $236 · 2025 $356
Food & beverage: $356
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 5 | $111 |
| ABIOMED | 3 | $103 |
| E.R. Squibb & Sons, L.L.C. | 1 | $58 |
| Kestra Medical Technology Services, Inc. | 2 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $32 |
Products named: LEQVIO, CAMZYOS, Assure WCD, ENTRESTO, LIVTENCITY.
Industry payments across TX — which companies pay providers there.
